Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozibafusp alfa in rheumatoid arthritis
NCT03156023Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2017
- Primary completion
- Oct 2019
- Modality
- Bispecific Antibodies, Peptides
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Rozibafusp Alfa with Placebo (2 arms). Primary endpoint: Number of Participants With Treatment-emergent Adverse Events up to 34 weeks. Started Aug 2017; status: completed.
02
Drugs
rozibafusp alfa
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03156023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03156023.